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Abstract 
Achieving the combination of delayed and immediate release of a vaccine from a delivery 
device without applying external triggers remains elusive in implementing single 
administration vaccination strategies. Here a means of vaccine delivery is presented, which 
exploits osmosis to trigger delayed burst release of an active compound. Poly(ε-caprolactone) 
capsules of 2 mm diameter were prepared by dip-coating, and their burst pressure and release 
characteristics were evaluated. Burst pressures (in bar) increased with wall thickness (t in 
mm) following Pburst = 131.t + 3.4 (R2 = 0.93). Upon immersion in PBS, glucose solution-
filled capsules burst after 8.7 ± 2.9 days. Copolymers of hydrophobic ε -caprolactone and 
hydrophilic polyethylene glycol were synthesized and their physico-chemical properties were 
assessed. With increasing hydrophilic content, the copolymer capsules showed increased 
water uptake rates and maximum weight increase, while the burst release was earlier: 5.6 ± 
2.0 days and 1.9 ± 0.2 days for 5 and 10 wt% polyethylene glycol, respectively. The presented 
approach enables the reproducible preparation of capsules with high versatility in materials 
and properties, while these vaccine delivery vehicles can be prepared separately from, and 
independently of the active compound. 
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Introduction 
Immunization has played a significant role in the widespread prevention and eradication of 
disease throughout the world, ever since the development of the smallpox vaccine in the 18th 
century (Ada et al., 1999). Therefore, it is not surprising that immunization programs have 
become an integral component of government health care systems throughout the developed 
and developing world (Amorij et al., 2012; Chen et al., 2011). Immunization involves 
introducing a pathogen-specific antigen to intentionally elicit an immune response. This 
primes the body’s immune system to respond to the pathogen, to provide protection against 
future exposure via natural transmission (Ada et al., 1999; Ada and Peter, 1998). 
One of the current challenges with immunization technology is that, for many vaccines to 
achieve complete immune protection, the patient requires a secondary dose of the vaccine at a 
specific time interval following the original vaccine administration (Ada and Peter, 1998). For 
example, in many countries, infants receive 8 different vaccines during their first 12 months 
of life, with up to 5 separate administrations or ‘booster shots’ for each vaccine. Timely 
administration of booster shots can be challenging, particularly where access to medical care 
is limited, such as in remote communities and developing countries, and for the immunization 
of wildlife (Kollipara et al., 2012) where recapture of each animal can be difficult. In some 
cases, even with an established and accessible medical system, patients do not receive timely 
administration of vaccines due to reasons such as migrating populations, inconvenience, 
discomfort, lack of education about the importance of the repetitive administration or 
misconceptions on perceived dangers of vaccination. 
The development of single-administration vaccines (SAV) has been a growing area of interest 
within the immunology and biomaterials science fields for several decades. SAVs are of 
particular interest for two main reasons: 1) to eliminate the need for booster shots, 
significantly reducing logistical costs associated with repeat administrations and 2) to ensure 
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the optimal time-delay between primary and secondary exposure to the antigen, resulting in 
maximum immunity against the pathogen. Approaches to release of antigens in a controlled 
manner are mostly based on liposomes, unilamellar vesicles, emulsions, degradable polymeric 
microparticles or self-exploding micro capsules (De Geest et al., 2009; Zhao and Leong, 
1996). The use of biodegradable microparticles administered by subcutaneous injection is 
perhaps the most commonly reported strategy (Cleland, 1999). There are several variations to 
the technology, with regards to the polymer matrix formulation including polylactide, 
polylactide-glycolide, polyethylene glycol, collagen, poly(ε-caprolactone), copolymers and 
blends, but essentially all of these involve the encapsulation of the antigen in a biodegradable 
polymer matrix. The release kinetics from biodegradable microparticles is usually triphasic: 
initial release of antigen from the surface of the microparticle followed by a lag period and 
then a continuous diffusion release phase. In most cases, the continuous diffusive release 
phase is in the order of weeks. This is not a desirable release profile as it does not mimic the 
instantaneous, concentrated antigen dose experienced with traditional needle injections, which 
could lead to induced tolerance (Cleland, 1999) as well as potentially hindering clinical 
approval. Furthermore, the quantity of antigen released at the maximal release load, is 
significantly less than total antigen quantity that is introduced in the production process. This 
implies that higher quantities of active compound are required during production of the 
microparticles, resulting in higher production costs. 
Numerous approaches have been used to prepare microcapsules with burst release 
characteristics designed to release a drug payload under certain conditions. Stimuli include 
high temperature (Volz et al., 2007), reducing reagents (Zhang et al., 2011), light (Bédard et 
al., 2010) and slightly acidic conditions (Zhang et al., 2012). Although elegant, none of these 
methods utilize suitable triggers for subcutaneous in vivo release. A more applicable approach 
exploited by De Geest et al. is to use osmotic pressure as the triggering mechanism to cause 
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physical rupture of a vaccine-containing capsule (De Geest et al., 2008; De Geest et al., 2009). 
While there have been various osmotically controlled drug delivery technologies reported in 
literature, these systems generally endeavor to achieve zero-order release kinetics, i.e. 
continuous release and, as previously mentioned, this is not the desired release kinetics for 
vaccine delivery. 
De Geest et al. achieved instantaneous delayed release using polyelectrolyte capsules filled 
with dextran-methacrylate hydrogel, which degrades via hydrolysis at a rate influenced by the 
crosslinking density. The concept of polyelectrolyte microcapsules in vaccine technology had 
previously been used to improve the delivery efficiency of DNA plasmids to the cytoplasm by 
reducing nuclease attack, thereby enhancing the antibody response, but not as a delay 
mechanism (Selina et al., 2009; Singh et al., 2000). By using a similar polyelectrolyte shell 
but introducing a dextran core, De Geest et al. were able to regulate the osmotic pressure, 
such that over time the degradation of the dextran causes a gradual increase in osmolarity 
resulting in higher internal hydrostatic pressure, until the capsules rupture and release their 
contents. A number of limitations remain with the self-exploding microcapsule technology, 
being variations in the size of microparticles leading to a spread in the burst times, potential 
redistribution of microcapsules throughout, or clearance from the body, as well as the 
impossibility to remove the particles in case of adverse events. 
Here we demonstrate a novel delivery platform to overcome most of the restrictions of current 
multiphasic vaccine delivery systems. We hypothesize that polymer tubes containing a model 
dye together with glucose as an osmotically active agent (osmogent) will allow slow influx of 
water at a controlled rate, ultimately resulting in bursting of the membrane as the hydrostatic 
pressure overcomes the burst pressure of the capsule, thus instantaneously releasing the 
payload (Figure 1). Osmotically activated capsules were prepared from a series of PCL and 
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PCL-PEG copolymers with varying water permeability. The polymers and capsules were 
characterized, and the proof of concept of delayed burst delivery was demonstrated. 
Materials and Methods 
Polymers: Poly(ε-caprolactone) (PCL) was used as received (Perstorp, CAPA 6500). Linear 
polyethylene glycol (PEG, Fluka (8 and 20 kg mol-1) and Sigma Aldrich (35 kg mol-1)) was 
first dried by azeotropic distillation with toluene using Dean Stark apparatus, and then 
employed as macro-initiator for the preparation of PCL-PEG-PCL triblock copolymers by 
ring opening polymerization of ε-caprolactone (Sigma Aldrich), for 2 days at 130 °C in the 
presence of Sn(Oct)2 (Sigma Aldrich) as a catalyst, under an argon atmosphere. The polymers 
were then dissolved in chloroform and precipitated from ethanol (10 % and 20 % PEG) or 
diethyl ether (30 % PEG), filtered and air-dried followed by vacuum drying. Targeted 
molecular weights of the co-polymers were between 66 and 100 kg mol-1. For simplicity, the 
nomenclature for the copolymers is xPEG, in which x is the intended weight percentage of 
PEG (making 100-x the intended weight percentage of PCL). 
Proton nuclear magnetic resonance spectroscopy (1H-NMR, Bruker Avance 400 MHz) was 
used to confirm PEG/PCL molar ratio and purity of the products. Differential scanning 
calorimetry was performed using a DSC-Q100 (TA Instruments) at a rate of 10 °C min-1 to 
determine melting and crystallization characteristics. The purified polymers were processed 
into 1 mm thick sheets by compression molding (140 °C, 14 MPa) using a custom made 
heated press, prior to cutting dumbbell shaped specimen for tensile testing (Instron 
MicroTester equipped with 500 N load cell) at a strain rate of 30 % min-1. 
Tubes: Tubes were fabricated by dip-coating. Steel rods (10-20 cm length, 2.0 mm diameter) 
were dipped into a 10% w/v polymer solution in CHCl3 and then rotated at 2 rpm at an angle 
of 45° for 2 min. The process was repeated twice. Tubes were annealed on the mandrel under 
partial vacuum (7 mbar) in a glass tube immersed in water at 70°C for 15 min. The tube was 
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decapped and immersed in ethanol for 1 h prior to removal from the rod. The middle section 
of the tube was used to ensure homogenous wall thickness. 
Burst pressure tests were performed at room temperature (Instron MicroTester equipped with 
500 N load cell) at 5 mm min-1, corresponding to 83 µL min-1. Tubes were end-capped on one 
side, filled with water and mounted onto a 14 G needle (2.1 mm outer ∅) attached to a 1 mL 
glass syringe (Figure 4A) mounted in a custom-made, rig assembled from laser cut 
polymethyl methacrylate parts. The joint between tube and needle was fixed and made leak-
free with a 4 mm shaft clamp and two O-rings (1.8 mm ∅). Recorded forces were corrected 
for friction force from the plunger (measured with non-capped tube filled with water) and 
divided by the surface area of the plunger (16.6 mm2) to yield pressure values, while the 
injected volume was calculated as the displacement multiplied by ditto number. The 
compliance of the setup was found to be negligible. 
Osmosis-driven delayed burst release: Tubes (30 mm long, inner diameter 2.0 mm, wall 
thickness 0.2 mm) made out of PCL, 5PEG and 10PEG were end-capped on one side, filled 
with saturated glucose supplemented with blue food dye with a syringe, and end-capped air-
free on the other side. Specimen (n=3x9) were weighed, immersed in PBS at 37 °C and their 
weights recorded at intervals. Four out of 27 tubes leaked directly from immersion and were 
disregarded. The first moment of decreased weight (always corresponding with discoloration 
of the immersion medium) was taken as the burst moment. 
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Results 
 
1. Polymer properties 
PCL-PEG-PCL triblock copolymers were successfully synthesized with PEG contents close 
to the intended values (Table I). As PCL and PEG homopolymers have comparable melting 
temperatures, the resulting copolymers melt within the same tight range of 54-56 °C. The 
melting enthalpy was slightly higher for the PEG-containing polymers than for PCL 
homopolymer. Crystallization occurred just above room temperature (25-31 °C) at the applied 
cooling rate of 10 °C min-1. 
As intended, the equilibrium water uptake in PBS (osmotic pressure 7.7 bar (Silbernagl and 
Despopoulos, 2008)) increases significantly as the fraction of the hydrophilic PEG component 
is increased. The equilibrium water uptake in saturated glucose (909 g L-1, osmotic pressure 
165 bar) is considerably lower for all polymers. The difference in water concentration, which 
is the driving force for the inflow of water into a glucose solution-filled polymer capsule in an 
aqueous environment, increases sharply with PEG content. 
The stiffness of all polymers is comparable in the dry state, namely 250-350 MPa (Figure 2A). 
More importantly, with increasing PEG content, thus increasing uptake of plasticizing water, 
the stiffness is reduced by 8 % for PCL up to 65 % for 30PEG. The tensile strength is not 
considerably affected by the uptake of water, but does decrease with increasing PEG content 
(Figure 2B). This is an important parameter determining the lag time for delayed burst 
delivery. Upon prolonged immersion in PBS at 37 °C, the ultimate strength slightly decreases 
as an effect of polymer degradation by hydrolysis. Not unexpectedly, the rate of degradation 
is faster for the more hydrophilic polymers, but in no case is the loss in tensile strength 
significant within the timeframe in which is vaccine delivery is intended (Figure 2C).  
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2. Capsule characteristics 
Tubular parts were fabricated by solution dip coating onto a metal mandrel followed by 
thermal annealing to remove irregularities and obtain a solid, homogeneous tube wall (Figure 
3A). Dip coating was successfully performed with all polymers, however was more facile for 
lower PEG content. Solvent evaporation led to a rough porous surface (Figure 3B) with 
increased roughness for higher PEG content, however this was evened out by thermal 
annealing (Figure 3C). Tubes typically had an internal diameter of 2 mm (corresponding to 
the diameter of the mandrel) and wall thickness between 0.1 and 0.4 mm. Wall thickness 
could easily be varied by changing the number of dips for dip coating. The wall thickness was 
homogenous throughout the tube (Figure 3A); a typical wall thickness distribution (Figure 
3D) shows a standard deviation of 0.021 mm at an average of 0.171 mm. 
Tubular capsules were filled with liquid using a micropipette, followed by sealing. Sealing 
was performed by inserting a cylindrical PCL plug into the distal part of the tube, followed by 
melt-sealing of the tube wall onto the plug. For a reproducible sealing process, a sealing 
device was developed (Figure 3E). It comprises one copper block which contains the tube 
with plug and is used at room temperature (blue in the CAD drawing), and a copper block that 
is assembled onto the first block with guiding rigs after pre-heating (red in the CAD drawing), 
effectively melt-sealing the plug into the tube. Quick solidification follows as the smaller hot 
block conducts its heat to the larger cold block, which acts as a heat sink. 
The burst pressures of produced tubes were tested using a custom-made device that allows 
controlled inflation of the tube with liquid from a syringe, using a mechanical testing setup 
(Figure 4A). Testing of tubes of comparable geometry but from different polymers showed a 
minor decrease in burst pressure when PEG content was increased from 0 to 5 to 10 %, but a 
sharp decline when further increasing PEG content to 20 and 30 % (Figure 4B, C). These 
trends are consistent with the changes in measured uniaxial tensile strengths (Figure 2B). The 
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burst pressures of PCL tubes of varying wall thickness were systematically lower than 
predicted using equations S1 and S2 (Supplementary Info) with the measured tensile strength 
as input parameter. However, the values were highly reproducible, with linear dependence on 
wall thickness t: Pburst = 131.t + 3.4 with R² = 0.93 (Figure 4D). 
 
3. Osmosis-driven delayed burst release experiment 
Tubes filled with osmogent and dye (as a model compound) steadily increased in mass due to 
water uptake when immersed in PBS, and showed delayed burst release behavior as 
confirmed by the release of dye (Figure 5). With increasing PEG content in the capsule 
polymer, the water uptake was higher and more rapid, and the dye was released earlier. PCL 
tubes burst within 8.7 ± 2.9 days, 5PEG tubes in 5.6 ± 2.0 days and 10PEG tubes in 1.9 ± 0.2 
days. The 20PEG and 30PEG materials were not included because of their poor mechanical 
robustness and high water uptake. 
 
Discussion 
Complete immune protection upon a single administration is the holy grail of vaccine delivery 
research. In this research endeavor, two main approaches can be distinguished: the use of 
alternative immunogenic compounds, or the controlled release of antigen using a biomaterials 
approach. The first approach, which includes the use of defined subunit antigens, viruses (live 
or attenuated) or vectors (viral or DNA) encoding part of the pathogen genome, is not without 
risks (while subunit vaccines may require strong adjuvants to elicit protective immunity). The 
research into biomaterials-based controlled release of antigens is mainly divided into the use 
of microparticles or self-exploding (osmotic) microcapsules, extended by the monolithic 
osmotic capsules introduced here. These osmotic capsules present a versatile delivery 
platform, in which the lag time for burst release may be tailored through the choice of 
10 
 
  
polymer, mechanical properties, degradation profile, capsule wall thickness/geometry and 
concentration of the osmogent.  
In this study, osmosis-driven delayed burst delivery from monolithic implantable capsules 
was demonstrated, including experimental data studying the influence of polymer 
hydrophilicity on burst time. The choice of PCL and PCL-PEG-PCL as the capsule materials 
was based on their widely-accepted use as implantable materials (characterized by mild 
implantation biology and minor fibrous tissue encapsulation (Woodruff and Hutmacher, 
2010)), ease of processing and the ability to vary the hydrophilic/hydrophobic balance 
depending on PEG content. After the intended release of vaccine, PCL is fully degraded after 
2-3 years in the subcutaneous environment, largely independent of implant geometry (Sun et 
al., 2006); PEG-containing copolymers can be expected to degrade faster due to higher water 
uptake hence faster hydrolytic degradation (Figure 2C). The water uptake of glucose-filled 
PCL and copolymer capsules was faster than intuitively expected based on the hydrophobic 
nature of PCL (water uptake of 0.5%, Table I). Therefore, a 5% PEG copolymer was 
synthesized and added to the range for the osmosis-driven burst release experiment. Based on 
the observed lag times for burst delivery compared to the desired intervals between prime and 
booster shots, PCL homopolymer will be the most suitable candidate of this set of materials 
for the intended purpose. The suitability of wall thickness as a control parameter was 
demonstrated by showing the highly predictable increase in burst pressure with thickness 
(Figure 4D). The effect of these and other design parameters (PEG content, osmogent 
concentration, internal diameter) can be evaluated quantitatively using a simple model similar 
to the one developed by Kuethe et al. (Kuethe et al., 1992). In our version, in particular the 
decline in water inflow due to dilution of the osmogent has been considered (Supplementary 
Info). In order to extend the burst lag time of PCL capsules from the current 8.7 days up to a 
more relevant time for booster shots (e.g. 35 days – a factor 4 times higher), one could, for 
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example, increase both geometrical parameters (diameter and wall thickness) by a factor 2. 
Alternatively, one could use internal diameter 3 mm with 0.4 mm wall thickness and a 
glucose solution of 425 g/L. Further decreasing the osmogent concentration is unwise, as this 
leads to a situation where at the calculated burst time osmotic and hydrostatic pressure are 
almost in equilibrium, which means an unpredictable delay time that is highly sensitive to 
small changes in properties or environmental conditions. To obtain longer delay times without 
increasing the capsule size, polymers with lower water permeability are required. Here we use 
the model to assess the influence of design parameters; calculation of absolute burst times 
requires all constituent parameters to be known, including the permeability of the polymer to 
water, and time-dependent mechanical behavior (e.g. creep). 
The use of monolithic osmotic capsules has many specific advantages over previously 
described approaches. Firstly, it is highly versatile as a wide range of polymers can be used 
and prepared into capsules with a range of delivery times from hours to potentially months. 
The fabrication process is simple, in this case dip coating was used, although for mass 
production for actual future use we envision the application of industrial melt extrusion 
techniques to produce polymer tubing with high accuracy and very low cost. Another 
advantage is that the choice of payload is independent from the capsule material or method of 
preparation. As the reservoir device is first prepared and then filled with osmogent and 
vaccine, the vaccine will not be exposed to any processing (e.g. heat or organic solvents). On 
the contrary, while PLGA microspheres have proven successful for the timely delivery of 
several antigens, this technology has not been applied to viruses or bacteria that make up a 
large part of existing vaccines (Cleland, 1999). The inevitable use of harsh organic solvents 
may destroy the active compounds. Furthermore, the payload will be incorporated 
quantitatively in the osmotic capsules. For microparticles or self-exploding microcapsules, 
loading efficiencies are often low and precise quantities and concentrations of the antigen 
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contained within the formulations unknown. In addition, existing vaccine formulations have 
the potential to be used with these osmotic capsules without substantial modification, 
provided the antigen remains stable inside the capsule up until its release and can be 
concentrated into the necessary volume (approximately 70 μL for the capsule size studied 
here). Ordinarily vaccine formulations are prepared as dilute solutions, however, capsule 
delivery would require concentration of the vaccine to enable the dosing required. Therefore, 
consideration of possible precipitation and inactivation should be given specific to the antigen 
used. Once implanted, the monolith will prevent redistribution throughout, or clearance of the 
active compounds from the body between the time of administration and the release. The 
other important advantage of the use of a single, monolithic device is that it ensures a single 
pulse of active compound.  
For this type of vaccination device to be translated to use in animals or humans, cost is a 
major consideration. Polymer tubing can be easily manufactured at low cost by extrusion 
methods. Sterilization, filling and capping can be done in an automated way and there are no 
costs for solvents or laborious processes. Typically, the material cost for a single delivery 
device (excluding vaccine) in the order of a few tens of cents (for 70 mg of a biodegradable 
polymer and 150 mg glucose). In summary, monolithic osmosis-driven delayed burst release 
capsules have many advantages when compared to microparticles and self-exploding 
microcapsules (Table II). The major disadvantage is the method of administration; the capsule 
needs to be implanted under the skin using a large diameter needle, as opposed to an 
intramuscular or intravenous injection. However, a device with similar geometry and stiffness 
(Implanon™ contraceptive) is being used successfully on a large scale in women whereby the 
application is performed by nurses and general practitioners without the need for specific 
training. Thus, existing methods of device implantation (Implanon™ applicator, a 14G needle 
with built-in plunger) can be employed with relative ease. One potential disadvantage is the 
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possibility of local hypertonicity within the interstitial fluid immediately after capsule burst 
due to the osmogent release. Some cell necrosis would be likely under these circumstances 
but would only be transient until isotonic conditions are re-established. To study the effects of 
osmogent-induced hypertonicity in vivo models would be required.  
To develop systems that release vaccines in a controlled manner following single 
administration, it should be considered that the current regimen of delivering single pulses at 
predetermined intervals may not be ideal. The current approach of repeated bolus injections 
has proven to work, but it may be the gold standard for its practicality rather than inducing the 
strongest, most long-lived immunologic response. Indeed, some studies suggest that rather 
than repeated bolus injections, exponentially increasing doses of antigen (mimicking pathogen 
replication) may illicit the strongest immune response (Johansen et al., 2008). Alternative 
approaches deliver decreasing vaccine doses in order to expand the highest affinity B and T 
cell responses. Yet another study showed that an initial pulse of antigen followed by a trickle 
delivery works equally well as pulsatile delivery (Spiers et al., 2000). The optimum dosing 
schedule will vary for different antigens and will have to be established using tools such as 
osmotic pumps (Cleland et al., 1996). Nevertheless, there is consensus on the fact that 
pulsatile release of any form will outperform a continuous release approach, as the latter 
potentially evoke a low-dose tolerance, where antibody titers are low and do not neutralize 
(Cleland et al., 1996; Spiers et al., 2000). The approach introduced here allows for multiple 
pulses by using multiple capsules, or one capsule containing multiple chambers that can each 
rupture and release at distinct time points. 
A major requirement for this and many other vaccine delivery systems to work is for the 
vaccine to remain active upon long-term storage in the body, including a relatively high 
temperature and hydrated condition. As proteins, antigens are prone to denaturation, and live 
organisms or viruses may be even more sensitive. Thorough stability tests will thus have to be 
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performed before any attempt of immunization with this delivery platform can be done. 
Possibly, active compounds can be further protected, e.g. by encapsulation in microparticles 
that will remain stable inside the capsule, but are degraded swiftly upon contact with body 
fluid after delayed burst delivery. 
Osmosis has been exploited for time-controlled release of active compounds in many forms, 
most commonly utilized to achieve sustained release. To that end, capsules filled with an 
active compound and an osmogent have a small orifice through which the drug is expelled in 
a sustained manner by swelling of the osmogent (Verma et al., 2002). The commercially 
available OROS™ system based on this technology has been employed for oral delivery of 
drugs in many therapeutic areas including cardiovascular medicine, endocrinology, urology, 
and central nervous system therapeutics (Conley et al., 2006). The release properties of such 
osmotic devices are to a large extent independent of physiological factors such as pH and the 
presence of enzymes, resulting in a high in vitro to in vivo correlation. In the absence of an 
orifice, the osmotic effect induces a gradual increase of the hydrostatic pressure inside the 
semi-permeable membrane. This pressure increase can be used to achieve instantaneous 
release after a lag period, when the burst pressure of the membrane is overcome.  
Drug release devices have also been reported where ejection of a plug, expansion of an orifice 
or rupturing of a membrane was triggered by an increased hydrostatic pressure after osmosis-
driven water uptake (Barzegar-Jalali et al., 2006; Schultz et al., 1997). Application to vaccine 
booster shots has been suggested (Gresser et al., 1995) and appropriate delay times have been 
shown for injectable systems such as the self-exploding osmotic microcapsules described 
above (De Geest et al., 2009; Stubbe et al., 2004). Monolithic devices however have typically 
been targeted at the gastrointestinal tract, and to our knowledge any reported delay time of 
such systems is within 48 h  (Reddy et al., 2009; Vipul and Moinuddin, 2012). In this study 
we prepared capsules that release their payload by burst delivery after 8.7 ± 2.9 days, and 
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suggested means of further extending the lag time based on a sophisticated version of existing 
models of delayed burst release. Analogously to the orifice-based osmotic systems, the 
behavior of the osmosis-driven delayed burst-release devices can be expected to be mostly 
independent of external factors, thus presenting a reliable platform for vaccine delivery. 
Conclusions 
In this work we presented a platform for vaccine delivery, exploiting osmosis to trigger 
delayed burst release of an active compound. The delivery vehicle is a polymer capsule that 
can be prepared separately from, and independently of the active compound. The lag time for 
burst delivery can be tailored through parameters relating to capsule material, capsule 
geometry and osmogent concentration. Upon immersion in PBS, glucose solution-filled 
capsules (of the same geometry) prepared from PCL-PEG copolymers with 0, 5 and 10 wt% 
PEG burst after 8.7 ± 2.9 days, 5.6 ± 2.0 days and 1.9 ± 0.2 days respectively. Furthermore, 
for PCL tubes with 2 mm internal diameter, the burst pressure increased with wall thickness 
(t) following Pburst = 0.131.t + 3.4, which was reproducible (R2 = 0.93) but systematically 
lower than predicted. A set of equations was postulated that allows to calculate hydrostatic 
pressure, volume increase and mechanical load of the capsule when one of the three is given, 
as well as to obtain a quantitative indication of burst delay time. 
 
Supplementary Information 
Supplementary Information is available on the equations governing osmosis-driven delayed 
burst delivery. 
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